Evidence map›Paper›PMID 40654585›Full record

ReviewNeuroscience applied2025

Harnessing brain-derived extracellular vesicles to support RDoC-based drug development.

I Magaraggia, J Krauskopf, J G Ramaekers, Y You, L de Nijs, J J Briedé, R Schreiber

Abstract readReview
In one paragraph

Review in Neuroscience applied, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Extracellular vesicles: key mediators inFrontiers in veterinary science · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

I MagaraggiaDepartment of Toxicogenomics, Faculty of Health, Medicine and Life Science, Maastricht University, P.O. 616, 6200, Maastricht, the Netherlands.
J KrauskopfDepartment of Toxicogenomics, Faculty of Health, Medicine and Life Science, Maastricht University, P.O. 616, 6200, Maastricht, the Netherlands.
J G RamaekersDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. 616, 6200 MD, Maastricht, the Netherlands.
Y YouDepartment of Neuroscience, Mayo Clinic, Jacksonville, 32224, FL, USA.
L de NijsDepartment of Fundamental Neuroscience, Section Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Faculty of Health, Medicine and Life Science, Maastricht University, P.O. 616, 6200, Maastricht, the Netherlands.
J J BriedéDepartment of Toxicogenomics, Faculty of Health, Medicine and Life Science, Maastricht University, P.O. 616, 6200, Maastricht, the Netherlands.
R SchreiberDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. 616, 6200 MD, Maastricht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Research Domain Criteria (RDoC) framework offers a dimensional and transdiagnostic approach to understanding complex neuropsychiatric and neurological disorders, facilitating the development of novel therapeutics. However, the integration of cellular and molecular brain processes into the RDoC framework is hindered by the lack of adequate biomarkers. This review explores the potential of brain-derived extracellular vesicles (BDEVs) isolated from biofluids as a source of non-invasive mechanistic biomarkers in RDoC-based drug discovery. We provide an overview of BDEVs, including their classification, biological functions, and current methodologies for isolation and characterization. We then discuss studies that have investigated BDEV cargo as mechanistic biomarkers in CNS drug studies, focusing on target engagement, treatment response, and toxicity. Additionally, we address important considerations and open questions regarding the characterization and validation of BDEVs in neuroscience research. Special emphasis is placed on the use of miRNA cargo within BDEVs as molecular readouts, highlighting their stability, regulatory roles, and potential to reflect dynamic changes in brain function. Finally, the review proposes strategies to further investigate the use of BDEV miRNA cargo as molecular readouts, underscoring its ability to provide insights into the molecular mechanisms underlying drug effects and their relevance to CNS drug discovery within the RDoC framework. Despite existing methodological and conceptual challenges, BDEVs represent a promising tool for advancing RDoC-based drug discovery.

Identifiers

PMID40654585
PMCPMC12244223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.